ABBVD.BA
ABBVIE INC News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 4,
"returned": 4,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "7edfddc8-e1c9-4e99-aceb-5a03c93623cf",
"title": "AbbVie Q1 Earnings Preview: No Repeat Of Last Year's Q1 Disappointment (ABBV)",
"description": "AbbVie soon releases Q1 2024 earnings and faces losing patent protection for its best-selling drug, Humira. Read why I expect a positive Q1 2024 from ABBV.",
"keywords": "",
"snippet": "Galeanu Mihai\n\nInvestment Overview - AbbVie In The Post Humira Era\n\nAbbVie Inc. (NYSE:ABBV), the Chicago, Illinois based Pharma giant, will announce its Q1 2024...",
"url": "https://seekingalpha.com/article/4684529-abbvie-q1-earnings-preview-no-repeat-of-last-years-first-quarter-disappointment",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1698211768/image_1698211768.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2024-04-18T17:46:38.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "ABBVD.BA",
"name": "ABBVIE INC",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 35.73008,
"sentiment_score": 0.086782,
"highlights": [
{
"highlight": "Galeanu Mihai\n\nInvestment Overview - <em>AbbVie</em> In The Post Humira Era\n\n<em>AbbVie</em> <em>Inc</em>. (NYSE:ABBV), the Chicago, Illinois based Pharma giant, will announce its Q1 2024 earnings pre-market next Friday, 26th. Analysts are forecasting earnings per share (\"EPS\") on a normalized basis of $2.28, and on a GAAP basis, $0.68, on projected revenues of $11.94bn.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Besides its strong dividend, <em>AbbVie</em> is probably best known for marketing and selling what, for a long period during the past and present decade, was the world's best-selling drug - Humira.",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "As well as financial headwinds, i.e., rising inflation, high interest rates, currency fluctuations, cost of debt etc., <em>AbbVie</em> faces other issues.",
"sentiment": 0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "Nevertheless, <em>AbbVie</em> has been one of the best-performing Big Pharma companies to be invested in long-term.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AbbVie</em> 2023 Earnings Overview - Impact Of Humira LOE\n\nAcross 2023, <em>AbbVie</em> delivered revenues of $54.32bn, down 6.4% year-on-year, and largely due to the Humira LOE. Despite Skyrizi revenues growing by 50% year-on-year, to $7.8bn, and Rinvoq revenues by 57%, to $3.97bn, AbbVie's immunology division revenues fell by 10% year-on-year, to $26.14bn.",
"sentiment": -0.0529,
"highlighted_in": "main_text"
},
{
"highlight": "The fact that <em>AbbVie</em> was able to grow its share price in 2023 - the year in which its mega-blockbuster drug - responsible for nearly 40% of its total revenues in 2022 - saw revenues decline by almost $7bn, speaks to the faith the market has in <em>AbbVie</em> management's good stewardship.",
"sentiment": 0.8481,
"highlighted_in": "main_text"
},
{
"highlight": "Of course, if <em>AbbVie</em> misses its own targets, the market may begin to worry, hence Q1 2024 earnings should be straightforward to interpret.",
"sentiment": -0.5859,
"highlighted_in": "main_text"
},
{
"highlight": "s (PFE) Xeljanz in Rinvoq's case, for example - <em>AbbVie</em> will want to avoid missing Wall Street's expectations for the second year in a row.",
"sentiment": -0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AbbVie</em> pipeline (Investor Presentation)\n\nMy own forecasts - which I will share in a future post - support <em>AbbVie</em> being on track to achieving >$80bn of revenues by the end of the decade, buoyed by a >$30bn revenue immunology division, and a >$15bn neuroscience division, and a >$10bn oncology division.",
"sentiment": 0.5994,
"highlighted_in": "main_text"
},
{
"highlight": "Naturally, there are many obstacles in the way of that target, but it is based on forecasts that are broadly in line with <em>AbbVie</em> management's internal expectations.",
"sentiment": -0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AbbVie</em> Q1 Earnings Preview: No Repeat Of Last Year's Q1 Disappointment (ABBV)",
"sentiment": -0.6705,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "1833fb7b-dd04-49b8-80e0-3d456a9a3de3",
"title": "Global Biochips Market Size and Share to Grow by 2030, Accesses DelveInsight | Key Players in the Market - Thermo Fisher Scientific, Agilent Technologies, GE Healthcare, Qiagen, Abbott, Hoffmann La-Ro",
"description": "The biochips market is projected to experience substantial growth with a remarkable CAGR between 2024 and 2030. This expansion is driven by factors such as...",
"keywords": "DelveInsight Business Research LLP, Biochips, Biochips Market, Biochips Market Size, Biochips Trials, Biochips FDA, Biochips EMA, Biochips Companies",
"snippet": "New York, USA, April 18, 2024 (GLOBE NEWSWIRE) -- Global Biochips Market Size and Share to Grow by 2030, Accesses DelveInsight | Key Players in the Market - The...",
"url": "https://www.globenewswire.com/news-release/2024/04/18/2865711/0/en/Global-Biochips-Market-Size-and-Share-to-Grow-by-2030-Accesses-DelveInsight-Key-Players-in-the-Market-Thermo-Fisher-Scientific-Agilent-Technologies-GE-Healthcare-Qiagen-Abbott-Hoff.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/dbcddd65-71dd-4559-8875-ae89ac4f96db",
"language": "en",
"published_at": "2024-04-18T17:00:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "ABBVD.BA",
"name": "ABBVIE INC",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 10.000982,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Hoffmann-La Roche Ltd, <em>AbbVie</em> <em>Inc</em>., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, BAYER AG., Celldex Therapeutics Inc., Alaunos Therapeutics, Inc., Astellas Pharma Inc., Genentech, Inc., Sandoz International GmbH, and BeiGene, among others.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "7af72deb-0519-4e1a-989e-ed9d841ff67b",
"title": "Market Analysis: Regeneron Pharmaceuticals And Competitors In Biotechnology Industry - Regeneron Pharmaceuticals (NASDAQ:REGN)",
"description": "",
"keywords": "",
"snippet": "Loading... Loading...\n\nIn today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess...",
"url": "https://www.benzinga.com/insights/news/24/04/38317079/market-analysis-regeneron-pharmaceuticals-and-competitors-in-biotechnology-industry",
"image_url": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
"language": "en",
"published_at": "2024-04-18T15:00:49.000000Z",
"source": "benzinga.com",
"relevance_score": null,
"entities": [
{
"symbol": "ABBVD.BA",
"name": "ABBVIE INC",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 17.047462,
"sentiment_score": 0.34,
"highlights": [
{
"highlight": "Company P/E P/B P/S ROE EBITDA (in billions) Gross Profit (in billions) Revenue Growth Regeneron Pharmaceuticals Inc 25.93 3.81 7.81 4.56% $1.28 $2.92 0.58% <em>AbbVie</em> <em>Inc</em> 60.39 28.07 5.36 6.94% $3.85 $8.6 -5.42% Amgen Inc 21.14 22.71 5.04 11.05% $3.05 $5.08 19.84% Vertex Pharmaceuticals Inc 28.30 5.78 10.38 5.68% $1.22 $2.15 9.34% Gilead Sciences Inc 14.88",
"sentiment": 0.34,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "f3e42be5-9375-4243-9fb6-8a749ea713bf",
"title": "Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis",
"description": "− Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis who were treated with upadacitinib with a 26-week steroid taper regimen achieved...",
"keywords": "Markets",
"snippet": "− Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg)...",
"url": "https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/Phase-3-SELECT-GCA-Study-of-Upadacitinib-RINVOQ-Showed-Positive-Results-in-Patients-With-Giant-C-46468584/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
"language": "en",
"published_at": "2024-04-18T12:32:09.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "ABBVD.BA",
"name": "ABBVIE INC",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 15.434505,
"sentiment_score": 0.17781,
"highlights": [
{
"highlight": "., April 18, 2024 /PRNewswire/ -- <em>AbbVie</em> (NYSE: ABBV) today announced positive top-line results from SELECT-GCA, a Phase 3, multicenter, randomized, double-blind, placebo-controlled study, showing upadacitinib (RINVOQ®; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remissiona from week",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "of patients receiving placebo in combination with a 52-week steroid taper regimen (p=0.0019).1\n\n\"Many people living with GCA continue to suffer from the potentially debilitating symptoms of this disease, with limited treatment options available to them,\" said Kori Wallace, M.D., Ph.D., vice president, global head of immunology clinical development, <em>AbbVie</em>",
"sentiment": -0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "If you are having difficulty paying for your medicine, <em>AbbVie</em> may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.\n\nGlobally, prescribing information varies; refer to the individual country product label for complete information.",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>AbbVie</em> in Rheumatology\n\nFor more than 20 years, <em>AbbVie</em> has been dedicated to improving care for people living with rheumatic diseases.",
"sentiment": 0.8402,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>AbbVie</em>\n\nAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow.",
"sentiment": 0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "For more information about <em>AbbVie</em>, please visit us at www.abbvie.com. Follow @<em>abbvie</em> on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.\n\nForward-Looking Statements\n\nSome statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AbbVie</em> cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements.",
"sentiment": -0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AbbVie</em> undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.\n\n<em>AbbVie</em>. Data on file ABVRRTI78418. Ameer MA, Peterfy RJ, Khazaeni B. Giant cell arteritis.",
"sentiment": -0.296,
"highlighted_in": "main_text"
},
{
"highlight": "North Chicago, IL : <em>AbbVie</em> <em>Inc</em>.; 2023. Pipeline – Our Science | <em>AbbVie</em>. 2023. Available at: https://www.abbvie.com/our-science/pipeline.html. Accessed April 17, 2024 . A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants with Giant Cell Arteritis (SELECT-GCA). ClinicalTrials.gov.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "View original content to download multimedia:https://www.prnewswire.com/news-releases/phase-3-select-gca-study-of-upadacitinib-rinvoq-showed-positive-results-in-patients-with-giant-cell-arteritis-302120893.html\n\nSOURCE <em>AbbVie</em>",
"sentiment": 0.3182,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "ABBVD.BA",
"total_documents": 4,
"sentiment_avg": 0.15114800073206425
}
]
}
Other details
Exchange
- Buenos Aires Stock Exchange
- equity
- N/A
- ar